JP6914950B2 - Ｂ型肝炎ウイルスに対するワクチン - Google Patents

Ｂ型肝炎ウイルスに対するワクチン Download PDF

Info

Publication number
JP6914950B2
JP6914950B2 JP2018541546A JP2018541546A JP6914950B2 JP 6914950 B2 JP6914950 B2 JP 6914950B2 JP 2018541546 A JP2018541546 A JP 2018541546A JP 2018541546 A JP2018541546 A JP 2018541546A JP 6914950 B2 JP6914950 B2 JP 6914950B2
Authority
JP
Japan
Prior art keywords
hbv
arenavirus
protein
infectious
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018541546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536433A (ja
JP2018536433A5 (https=
Inventor
モナス トーマス
モナス トーマス
コーエン キャサリン
コーエン キャサリン
バウムガルトル‐ストラッセル ベラ
バウムガルトル‐ストラッセル ベラ
Original Assignee
ホオキパ バイオテック ジーエムビーエイチ
ホオキパ バイオテック ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホオキパ バイオテック ジーエムビーエイチ, ホオキパ バイオテック ジーエムビーエイチ filed Critical ホオキパ バイオテック ジーエムビーエイチ
Publication of JP2018536433A publication Critical patent/JP2018536433A/ja
Publication of JP2018536433A5 publication Critical patent/JP2018536433A5/ja
Priority to JP2021116562A priority Critical patent/JP2021182922A/ja
Application granted granted Critical
Publication of JP6914950B2 publication Critical patent/JP6914950B2/ja
Priority to JP2023180121A priority patent/JP7777907B2/ja
Priority to JP2025194235A priority patent/JP2026036693A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018541546A 2015-11-04 2016-11-03 Ｂ型肝炎ウイルスに対するワクチン Active JP6914950B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021116562A JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン
JP2023180121A JP7777907B2 (ja) 2015-11-04 2023-10-19 Ｂ型肝炎ウイルスに対するワクチン
JP2025194235A JP2026036693A (ja) 2015-11-04 2025-11-13 Ｂ型肝炎ウイルスに対するワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
US62/250,639 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021116562A Division JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン

Publications (3)

Publication Number Publication Date
JP2018536433A JP2018536433A (ja) 2018-12-13
JP2018536433A5 JP2018536433A5 (https=) 2020-03-26
JP6914950B2 true JP6914950B2 (ja) 2021-08-11

Family

ID=57249796

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018541546A Active JP6914950B2 (ja) 2015-11-04 2016-11-03 Ｂ型肝炎ウイルスに対するワクチン
JP2021116562A Pending JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン
JP2023180121A Active JP7777907B2 (ja) 2015-11-04 2023-10-19 Ｂ型肝炎ウイルスに対するワクチン
JP2025194235A Pending JP2026036693A (ja) 2015-11-04 2025-11-13 Ｂ型肝炎ウイルスに対するワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021116562A Pending JP2021182922A (ja) 2015-11-04 2021-07-14 Ｂ型肝炎ウイルスに対するワクチン
JP2023180121A Active JP7777907B2 (ja) 2015-11-04 2023-10-19 Ｂ型肝炎ウイルスに対するワクチン
JP2025194235A Pending JP2026036693A (ja) 2015-11-04 2025-11-13 Ｂ型肝炎ウイルスに対するワクチン

Country Status (20)

Country Link
US (2) US11214598B2 (https=)
EP (2) EP3371316B1 (https=)
JP (4) JP6914950B2 (https=)
KR (2) KR20250107977A (https=)
CN (2) CN108779472B (https=)
AU (3) AU2016348675B2 (https=)
CA (1) CA3003557A1 (https=)
DK (1) DK3371316T3 (https=)
ES (1) ES2934698T3 (https=)
FI (1) FI3371316T3 (https=)
HR (1) HRP20221474T1 (https=)
HU (1) HUE060648T2 (https=)
IL (2) IL314371A (https=)
LT (1) LT3371316T (https=)
MX (2) MX2018005569A (https=)
PL (1) PL3371316T3 (https=)
PT (1) PT3371316T (https=)
SG (1) SG11201803474UA (https=)
SI (1) SI3371316T1 (https=)
WO (1) WO2017076988A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
IL314371A (en) * 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
IL265921B2 (en) 2016-10-14 2024-05-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
AU2020297011A1 (en) 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
JP2022536850A (ja) * 2019-06-18 2022-08-19 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
CN119770638A (zh) 2019-09-30 2025-04-08 吉利德科学公司 Hbv疫苗和治疗hbv的方法
JP7783631B2 (ja) * 2019-11-07 2025-12-10 ウニヴェルズィテート バーゼル ベクターとしてのアレナウイルス
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
US11718637B2 (en) 2020-03-20 2023-08-08 Gilead Sciences, Inc. Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
US20250034213A1 (en) * 2021-04-21 2025-01-30 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) * 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
EA004497B1 (ru) * 1998-12-04 2004-04-29 Байоджен, Инк. Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2006125983A1 (en) * 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CN103536915A (zh) * 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
EP2604695B1 (en) * 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
TWI555531B (zh) * 2009-08-07 2016-11-01 傳斯堅公司 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
EA028659B1 (ru) * 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
ES2646590T3 (es) 2012-01-24 2017-12-14 Sanford Health Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
US10342861B2 (en) 2014-05-27 2019-07-09 University Of Rochester Arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
PL3198008T3 (pl) 2014-09-22 2020-03-31 Regents Of The University Of Minnesota Układ wykorzystujący odwrotną genetykę wirusa pichinde i sposoby zastosowania
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
EP3365005B1 (en) 2015-10-23 2025-04-09 Institut Pasteur Recombinant mopeia virus and vaccine platform
IL314371A (en) * 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
US20190135875A1 (en) 2016-05-18 2019-05-09 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
EP3534943A2 (en) 2016-11-04 2019-09-11 Hookipa Biotech GmbH Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
CN108779472B (zh) 2022-09-09
EP3371316A1 (en) 2018-09-12
HRP20221474T1 (hr) 2023-01-06
KR102832178B1 (ko) 2025-07-11
KR20250107977A (ko) 2025-07-14
IL259077A (en) 2018-06-28
EP3371316B1 (en) 2022-10-19
US20220073568A1 (en) 2022-03-10
JP7777907B2 (ja) 2025-12-01
CN115948467A (zh) 2023-04-11
HUE060648T2 (hu) 2023-04-28
JP2018536433A (ja) 2018-12-13
NZ741950A (en) 2023-10-27
JP2024010027A (ja) 2024-01-23
AU2023200108A1 (en) 2023-02-16
US20180319845A1 (en) 2018-11-08
JP2026036693A (ja) 2026-03-05
CN115948467B (zh) 2026-04-24
BR112018009032A8 (pt) 2019-02-26
WO2017076988A1 (en) 2017-05-11
LT3371316T (lt) 2022-11-25
FI3371316T3 (fi) 2023-01-13
AU2023200108B2 (en) 2025-08-28
AU2025271193A1 (en) 2026-01-15
SG11201803474UA (en) 2018-05-30
BR112018009032A2 (pt) 2018-11-06
DK3371316T3 (da) 2023-01-23
SI3371316T1 (sl) 2023-02-28
IL259077B1 (en) 2024-08-01
IL259077B2 (en) 2024-12-01
ES2934698T3 (es) 2023-02-24
PT3371316T (pt) 2022-11-17
JP2021182922A (ja) 2021-12-02
AU2016348675B2 (en) 2022-11-17
IL314371A (en) 2024-09-01
PL3371316T3 (pl) 2023-02-13
MX2018005569A (es) 2018-12-19
EP4177348A1 (en) 2023-05-10
HK1255847A1 (en) 2019-08-30
CA3003557A1 (en) 2017-05-11
NZ781654A (en) 2025-06-27
US11214598B2 (en) 2022-01-04
CN108779472A (zh) 2018-11-09
MX2023013140A (es) 2023-11-28
AU2016348675A1 (en) 2018-05-17
KR20180082485A (ko) 2018-07-18

Similar Documents

Publication Publication Date Title
JP6914950B2 (ja) Ｂ型肝炎ウイルスに対するワクチン
CN105980570B (zh) Cmv疫苗
CN107921117A (zh) Hpv疫苗
TW201734208A (zh) Ｈｂｖ聚合酶突變體
JP2017535267A (ja) ワクチンベクターとしての３分節型アレナウイルス
HK40093198A (en) Vaccines against hepatitis b virus
HK40090610A (zh) 针对乙型肝炎病毒的疫苗
NZ741950B2 (en) Vaccines against hepatitis b virus
HK1255847B (en) Vaccines against hepatitis b virus
BR122024003112A2 (pt) Vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, uso de vetor viral, ácido nucleico isolado
BR122024003112B1 (pt) Vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, uso de vetor viral, ácido nucleico isolado
BR112018009032B1 (pt) Vetor viral de arenavírus infeccioso, composição farmacêutica ou imunogênica ou vacina, uso de um vetor viral, ácido nucleico isolado e uso do ácido nucléico
HK1263252A1 (en) Vaccines against hepatitis b virus
HK1263252B (en) Vaccines against hepatitis b virus
JP2019510089A (ja) ＨＢｓＡｇ及びＨＢｃＡｇを発現する失活化全組換えハンセヌラ・ポリモルファ細胞によるＢ型肝炎治療ワクチン
US20160215023A1 (en) Simple vaccines from dna launched suicidal flaviviruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180723

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210427

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210714

R150 Certificate of patent or registration of utility model

Ref document number: 6914950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531